FDA moves to remove GLP-1 medications from 503B Bulks List

• On April 30, 2026, the U.S. FDA introduced it’s contemplating eradicating GLP-1 drugs from the 503B bulks record.
• FDA’s 503B bulks record identifies drug substances that outsourcing amenities can use to compound drugs.
• Specialists agree eradicating GLP-1s from the 503B bulks record will considerably decrease the provision of compounded GLP-1s medicine.
• Sufferers should still be capable to obtain compounded GLP-1s by means of 503A compounding pharmacies, and take into account legit options for weight reduction.

In line with the FDA’s announcement, the group is asking for submitted feedback for or in opposition to this choice by the tip of June 2026 earlier than making their ultimate willpower.

Medical Information At this time spoke with 4 weight problems specialists to search out out extra about what the FDA’s 503B bulks record is, the potential future availability of compounded GLP-1 drugs, and what options could also be accessible for customers who could not be capable to afford the model identify medicine.

In line with Douglas Ewing, MD, FACS, DABOM, a board-certified bariatric surgeon and medical director of the Heart for Weight Loss and Metabolic Well being at Hackensack College Medical Heart, and affiliate professor of surgical procedure at Hackensack Meridian College of Medication in New Jersey, the FDA’s 503B bulks record identifies bulk drug substances that outsourcing amenities can use to compound drugs.

“These outsourcing amenities, regulated underneath part 503B of the Federal Meals, Drug, and Beauty Act, can produce bigger batches of compounded medicine than conventional 503A compounding pharmacies, which compound for particular person sufferers with particular prescriptions,” Ewing defined to MNT.

“The vital distinction between a drug on the 503B record and an FDA-approved treatment is the extent of scrutiny,” he continued.

“FDA-approved medicine endure a protracted and rigorous means of scientific trials to show their security, effectiveness, and high quality earlier than they are often marketed to the general public.”

“Compounded medicine, even from 503B amenities, don’t undergo this identical pre-market approval course of. Whereas 503B amenities are required to observe present Good Manufacturing Practices (cGMP), the compounded medicine themselves are usually not FDA-approved.”

If semaglutide and tirzepatide are faraway from the 503B bulks record, the provision of compounded GLP-1s would drop considerably, Michael Snyder, MD, FACS, FASMBS, DABOM, medical director of the Bariatric Surgical procedure Heart at Rose Medical Heart, founder and director of the Denver Heart for Bariatric Surgical procedure Basis, and in-house weight problems specialist at FuturHealth, instructed MNT.

“Most present compounded provide is produced by means of 503B outsourcing amenities, which might not be capable to compound them in bulk,” Snyder stated.

“There should still be restricted use underneath 503A compounding guidelines, the place a drugs is ready for a person affected person primarily based on a particular scientific indication, however that pathway is rather more restricted and never designed for widespread use.”

Jen Manne-Goehler, MD, ScD,assistant professor of medication at Harvard Medical College, agreed.

“There could also be some types of compounded GLP-1 medicine nonetheless accessible regardless of this choice,” Manne-Goehler instructed MNT.

”Particularly, the FDA’s choice to not embrace these GLP-1s on the majority compounding record wouldn’t be anticipated to have an effect on their use by 503A pharmacies. 503A compounding pharmacies compound in line with particular affected person prescriptions and are required by state boards of pharmacy to adjust to requirements.”

Due to the recognition and excessive demand of GLP-1 drugs, Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Heart at Orange Coast Medical Heart in Fountain Valley, CA, anxious this may increasingly drive some individuals to buy their treatment by means of a doubtlessly unsafe possibility.

“What I believe will occur is individuals will attempt to get the drugs from different sources outdoors the U.S., and that may be a little riskier,” Ali instructed MNT.

“You could possibly not be getting the treatment you might be shopping for, you might be getting one thing completely different or one thing perhaps even unsafe. So it might improve some danger if persons are going to go to sources outdoors of the U.S. to attempt to get these drugs.”

When requested in regards to the security of compounded GLP-1 medicine, Ewing stated that may be a complicated query and not using a easy “sure” or “no” reply. “The protection of compounded GLP-1s can range considerably relying on the supply,” he defined.

“There are legit compounding pharmacies that adhere to high-quality requirements. Nonetheless, the shortage of FDA approval and oversight for the ultimate compounded merchandise introduces inherent dangers.”

– Douglas Ewing, MD, FACS, DABOM

“Issues have been raised in regards to the potential for contamination, impurities, and incorrect dosages in some compounded merchandise,” Ewing continued.

“There have additionally been cases of pharmacies utilizing completely different salt types of semaglutide, which haven’t been accredited by the FDA and whose security and efficacy are unknown.”

Manne-Goehler stated that many stories have steered that the present compounded GLP-1s have the next variety of extreme unintended effects.

“For example, one study confirmed that compounded GLP-1 RAs are related to a higher danger of hostile occasions, security issues, and product high quality points in comparison with non-compounded merchandise,” she detailed.

“This can be as a result of decrease high quality compounding practices can lead to points with drug high quality, contamination or variations within the quantity of lively ingredient. A number of medical societies have really helpful in opposition to using compounded GLP-1 therapies.”

If compounded GLP-1s turn out to be much less accessible, Snyder stated there are nonetheless legit, evidence-based choices for weight reduction.

“That features different FDA-approved drugs for weight administration, in addition to structured medical weight loss programs that mix vitamin, behavioral assist, and ongoing scientific monitoring,” he continued.

“We additionally anticipate that over time these drugs will turn out to be extra inexpensive and protection ought to increase over time. However, clearly, not quickly.”

Ali stated there are different drugs accessible which might be perhaps accessible in generic kind as a result of they’ve been round longer, however they don’t work fairly the identical, or perhaps not even fairly in addition to the GLP-1 drugs.

“So there are different choices accessible, however they might be much less efficient,” he added.

For many who could also be anxious about affording the name-brand GLP-1 drugs, Ewing stated it’s all the time worthwhile to verify along with your insurance coverage supplier about their protection for weight-loss drugs, as formularies can change, and what was not lined earlier than is likely to be now.

“Many pharmaceutical corporations provide copay playing cards and affected person help packages that may considerably cut back the out-of-pocket price of brand-name GLP-1s for eligible people,” he detailed. “Providers like GoodRx can provide vital financial savings on brand-name GLP-1 drugs for these paying out-of-pocket.”

“It’s important for sufferers at present utilizing compounded GLP-1s to have an open dialog with their healthcare supplier to discover these options and develop a protected and efficient remedy plan transferring ahead,” Ewing added.